Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study

dc.contributor.authorVilar-Gomez, Eduardo
dc.contributor.authorAthinarayanan, Shaminie J.
dc.contributor.authorAdams, Rebecca N.
dc.contributor.authorHallberg, Sarah J.
dc.contributor.authorBhanpuri, Nasir H.
dc.contributor.authorMcKenzie, Amy L.
dc.contributor.authorCampbell, Wayne W.
dc.contributor.authorMcCarter, James P.
dc.contributor.authorPhinney, Stephen D.
dc.contributor.authorVolek, Jeff S.
dc.contributor.authorChalasani, Naga
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2019-08-21T20:26:46Z
dc.date.available2019-08-21T20:26:46Z
dc.date.issued2019-02-25
dc.description.abstractOBJECTIVE: One year of comprehensive continuous care intervention (CCI) through nutritional ketosis improves glycosylated haemoglobin(HbA1c), body weight and liver enzymes among patients with type 2 diabetes (T2D). Here, we report the effect of the CCI on surrogate scores of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis. METHODS: This was a non-randomised longitudinal study, including adults with T2D who were self-enrolled to the CCI (n=262) or to receive usual care (UC, n=87) during 1 year. An NAFLD liver fat score (N-LFS) >-0.640 defined the presence of fatty liver. An NAFLD fibrosis score (NFS) of >0.675 identified subjects with advanced fibrosis. Changes in N-LFS and NFS at 1 year were the main endpoints. RESULTS: At baseline, NAFLD was present in 95% of patients in the CCI and 90% of patients in the UC. At 1 year, weight loss of ≥5% was achieved in 79% of patients in the CCI versus 19% of patients in UC (p<0.001). N-LFS mean score was reduced in the CCI group (-1.95±0.22, p<0.001), whereas it was not changed in the UC (0.47±0.41, p=0.26) (CCI vs UC, p<0.001). NFS was reduced in the CCI group (-0.65±0.06, p<0.001) compared with UC (0.26±0.11, p=0.02) (p<0.001 between two groups). In the CCI group, the percentage of individuals with a low probability of advanced fibrosis increased from 18% at baseline to 33% at 1 year (p<0.001). CONCLUSIONS: One year of a digitally supported CCI significantly improved surrogates of NAFLD and advanced fibrosis in patients with T2D.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationVilar-Gomez, E., Athinarayanan, S. J., Adams, R. N., Hallberg, S. J., Bhanpuri, N. H., McKenzie, A. L., … Chalasani, N. (2019). Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. BMJ open, 9(2), e023597. doi:10.1136/bmjopen-2018-023597en_US
dc.identifier.urihttps://hdl.handle.net/1805/20480
dc.language.isoen_USen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.isversionof10.1136/bmjopen-2018-023597en_US
dc.relation.journalBMJ Openen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.sourcePMCen_US
dc.subjectKetogenic dieten_US
dc.subjectLiver fibrosisen_US
dc.subjectNon-alcoholic fatty liver diseaseen_US
dc.subjectType 2 diabetesen_US
dc.subjectVery low carb dieten_US
dc.subjectWeight lossen_US
dc.titlePost hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
bmjopen-2018-023597.pdf
Size:
451.98 KB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: